POLR1H and breast cancer: Considering the fact that ZNRD1 is oncogenic in breast cancer, the CAP treatment condition of 10 × 30 s is recommended to inhibit the MCF-7 cancer cell growth, because CAP in that condition, rather than 600 s, suppressed ZNRD1.